Imatinib is the only approved first-line drug for gastrointestinal stromal tumor (GIST) patients, especially for patients with advanced or metastatic tumors (1,2).
The utility and efficacy of
imatinib mesylate is unknown in the treatment of anal GIST.
M2 PHARMA-March 5, 2019-Breckenridge wins final US FDA approval for
Imatinib Mesylate Tablets ANDA
Global Banking News-March 5, 2019-Breckenridge wins final US FDA approval for
Imatinib Mesylate Tablets ANDA
M2 EQUITYBITES-March 5, 2019-Breckenridge wins final US FDA approval for
Imatinib Mesylate Tablets ANDA
K562 cells grown in RPMI 1640 were exposed to increasing concentrations of
imatinib (1-25 [micro]M), luteolin (25-200 [micro]M), apigenin (25-200 [micro]M), and 5-desmethyl sinensetin (25-200 [micro]M).
Currently several researcher used Hasford score to predict therapy response in CML chronic phase patients that received
imatinib. It was reported that no scoring system could predict the molecular response, but in the research conducted by Dybko et al, (2016) in Poland toward 88 newly diagnosed of CML chronic phase patients that received
Imatinib, it was reported that Hasford score were beneficial in predicting the molecular response in CML chronic phase patients.
Objectives: To determine the frequency of early molecular response in patients of chronic myeloid leukemia treated with
Imatinib and its association with baseline white blood cell (WBC) count and spleen size.
The EC approval is based on data from CA180-226, the largest prospective trial evaluating the safety and efficacy of Sprycel in pediatric patients newly diagnosed with CP-CML, and in those resistant to or intolerant of
imatinib. In the Phase 2 CA180-226 trial, at minimum two-year follow-up, patients with CP-CML resistant to or intolerant of
imatinib who received Sprycel demonstrated a cumulative major cytogenetic response rate of 55.2% 3 months into treatment, exceeding the defined threshold of clinical interest for the primary endpoint of the cohort and increasing over time to greater than 90% at 24 months.
WEDNESDAY, May 9, 2018 (HealthDay News) -- Prices of
imatinib (Gleevec) remained high even after a generic version was introduced, according to a study published in the May issue of Health Affairs.
The current standard of care is surgery for localized cases, and adjuvant
imatinib is recommended for tumors with a high risk of recurrence.